Biomarkers of oxidative damage in human disease

Clinical Chemistry

Volumn 52, Issue 4, 2006, Pages 601-623

  Dalle Donne, Isabella ^a   Rossi, Ranieri ^b   Colombo, Roberto ^a   Giustarini, Daniela ^b   Milzani, Aldo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDINONE; 4 HYDROXYNONENAL; 8 ISOPROSTAGLANDIN F2 ALPHA; ACROLEIN; BIOLOGICAL MARKER; GLUTATHIONE; GLUTATHIONE TRANSFERASE; ISOPROSTANE; ISOPROSTANE DERIVATIVE; MALONALDEHYDE;

ACUTE CHEST SYNDROME; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGING; ALCOHOL LIVER DISEASE; ANALYTIC METHOD; ASTHMA; ATHEROSCLEROSIS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; CREUTZFELDT JAKOB DISEASE; CROHN DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; DOWN SYNDROME; EVALUATION; HEART INFARCTION; HUMAN; HUNTINGTON CHOREA; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; INTERSTITIAL LUNG DISEASE; ISCHEMIA; LIVER CIRRHOSIS; LIVER FAILURE; NON INVASIVE MEASUREMENT; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; OXIDATIVE STRESS; PANCREATITIS; PHYSICAL DISEASE; PREDICTION; PREECLAMPSIA; PRIMARY BILIARY CIRRHOSIS; PSORIATIC ARTHRITIS; PULMONARY HYPERTENSION; REACTIVE ARTHRITIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SAMPLING; SENSITIVITY AND SPECIFICITY; SICKLE CELL ANEMIA; SKIN LEISHMANIASIS; SPINAL CORD INJURY; STEREOCHEMISTRY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DISEASE; DNA DAMAGE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 33645459044     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.061408     Document Type: Review

References (187)

1. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. New York: Oxford University Press, 1999:936pp.
2. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment [Review]. Drugs Aging 2001;18:685-716.
3. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis [Review]. Physiol Rev 2004;84:1381-478.
4. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases [Review]. Trends Mol Med 2003;9:169-76.
5. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, et al. Proteins as biomarkers of oxidative stress in diseases: the contribution of redox proteomics [Review]. Mass Spectrom Rev 2005;24:55-99.
6. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis [Review]. Annu Rev Pharmacol Toxicol 2004;44:239-67.
7. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? [Review]. Br J Pharmacol 2004;142:231-55.
8. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing [Review]. Nature 2000;408:239-47.
9. Finkel T. Oxidant signals and oxidative stress [Review]. Curr Opin Cell Biol 2003;15:247-54.
10. Dedon PC, Tannenbaum SR. Reactive nitrogen species in the chemical biology of inflammation [Review]. Arch Biochem Biophys 2004;423:12-22.
11. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease [Review]. Chem Res Toxicol 1997;10:485-94.
12. Linton S, Davies MJ, Dean RT. Protein oxidation and ageing [Review]. Exp Gerontol 2001;36:1503-18.
13. Schoneich C. Mass spectrometry in aging research [Review]. Mass Spectrom Rev 2005;24:701-18.
14. Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant damage to proteins and their application in study of human disease [Review]. Free Radic Biol Med 1999;27:1151-61.
15. Winterbourn CC, Buss H. Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods Enzymol 1999;300:106-11.
16. Levine RL, Wehr N, Williams JA, Stadtman ER, Shacter E. Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 2000;99:15-24.
17. Pryor WA. Bio-assays for oxidative stress status (BOSS). Amsterdam: Elsevier Science BV, 2001:286pp.
18. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, et al. Biomarkers [Review]. Mol Aspects Med 2002;23:101-208.
19. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. Adaptation of the Griess reaction for detection of nitrite in human plasma. Free Radic Res 2004;38:1235-40.
20. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations [Review]. Am J Physiol Regul Integr Comp Physiol 2004;286:R431-44.
21. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress [Review]. Prog Lipid Res 2003;42:318-43.
22. Carini M, Aldini G, Facino RM. Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins [Review]. Mass Spectrom Rev 2004;23:281-305.
23. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications [Review]. Trends Pharmacol Sci 2002;23:360-6.
24. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress [Review]. FASEB J 2004;18:1791-800.
25. Uchida K. Histidine and lysine as targets of oxidative modification [Review]. Amino Acids 2003;25:249-57.
26. Draper HH, Csallany AS, Hadley M. Urinary aldehydes as indicators of lipid peroxidation in vivo. Free Radic Biol Med 2000;29:1071-7.
27. Wilson R, Lyall K, Smyth L, Fernie CE, Riemersma RA. Dietary hydroxy fatty acids are absorbed in humans: implications for the measurement of 'oxidative stress' in vivo. Free Radic Biol Med 2002;32:162-8.
28. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation [Review]. Biochem J 1997;324:1-18.
29. Davies MJ. The oxidative environment and protein damage [Review]. Biochim Biophys Acta 2005;1703:93-109.
30. Grune T, Merker K, Sandig G, Davies KJA. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 2003;305:709-18.
31. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration [Review]. Biochem Biophys Res Commun 2003;305:776-83.
32. Requena JR, Levine RL, Stadtman ER. Recent advances in the analysis of oxidized proteins [Review]. Amino Acids 2003;25:221-6.
33. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins [Review]. Amino Acids 2003;25:207-18.
34. Stadtman ER, Moskovitz J, Levine RL. Oxidation of methionine residues of proteins: biological consequences [Review]. Antiox Redox Signal 2003;5:577-82.
35. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-τ in brains of patients with Alzheimer's disease. J Neurochem 2003;85:115-22.
36. Sitte N, Huber M, Grune T, Ladhoff A, Doecke WD, Zglinicki T, et al. Proteasome inhibition by lipofuscin/ceroid during postmitotic ageing of fibroblasts. FASEB J 2000;14:1490-8.
37. Grune T, Jung T, Merker K, Davies KJA. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease [Review]. Int J Biochem Cell Biol 2004;36:2519-30.
38. Berliner J, Heinecke JW. The role of oxidized lipoproteins in atherogenesis [Review]. Free Radic Biol Med 1996;20:707-27.
39. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus [Review]. Diabetologia 2000;43:550-7.
40. Heinecke JW. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress [Review]. Free Radic Biol Med 2002;32:1090-101.
41. Yoneyama Y, Sawa R, Suzuki S, Doi D, Yoneyama K, Otsubo Y, et al. Relationship between plasma malondialdehyde levels and adenosine deaminase activities in preeclampsia. Clin Chim Acta 2002;322:169-73.
42. Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflammation and asthma [Review]. Eur Respir J 2003;21:177-86.
43. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress [Review]. Nat Rev Drug Discov 2004;3:205-14.
44. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
45. Eckl PM, Ortner A, Esterbauer H. Genotoxic properties of 4-hydroxyalkenals and analogous aldehydes. Mutat Res 1993;290:183-92.
46. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications [Review]. Antioxid Redox Signal 1999;1:255-84.
47. Feng Z, Hu W, Tang MS. trans-4-Hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: a possible mechanism for lipid peroxidation-induced carcinogenesis. Proc Natl Acad Sci U S A 2004;101:8598-602.
48. Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal [Review]. Mol Aspects Med 2003;24:167-75.
49. Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci U S A 1992;89:4544-8.
50. Butterfield DA. Amyloid β-peptide(1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain [Review]. Free Radic Res 2002;36:1307-13.
51. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid β-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655-64.
52. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, et al. Lipid peroxidation in aging brain and Alzheimer's disease [Review]. Free Radic Biol Med 2002;33:620-6.
53. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging June 30, 2005 [Epub ahead of print].
54. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002;277:4644-8.
55. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, et al. Alzheimer-specific epitopes of τ represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005;38:746-54.
56. Jenner P. Oxidative stress in Parkinson's disease [Review]. Ann Neurol 2003;53:326-36.
57. Uchida K. Role of reactive aldehyde in cardiovascular diseases [Review]. Free Radic Biol Med 2000;28:1685-96.
58. Shao B, O'brien KD, McDonald TO, Fu X, Oram JF, Uchida K, et al. Acrolein modifies apolipoprotein α-I in the human artery wall. Ann N Y Acad Sci 2005;1043:396-403.
59. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, MacNee W, et al. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:490-5.
60. Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S, Hussain SN, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1116-24.
61. Klein T, Neuhaus K, Reutter F, Nusing RM. Generation of 8-epi-prostaglandin F(2α) in isolated rat kidney glomeruli by a radical-independent mechanism. Br J Pharmacol 2001;133:643-50.
62. Tsikas D, Schwedhelm E, Suchy MT, Niemann J, Gutzki FM, Erpenbeck VJ, et al. Divergence in urinary 8-iso-PGF(2α) (iPF(2α)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2α). Possible methodological, mechanistic and clinical implications. J Chromatogr B 2003;794:237-55.
63. 2-isoprostanes as an index of oxidative stress in vivo [Review]. Free Radic Biol Med 2000;28:505-13.
64. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation [Review]. Free Radic Res 2004;38:105-22.
65. Basu S, Helmersson J. Factors regulating isoprostane formation in vivo [Review]. Antioxid Redox Signal 2005;7:221-35.
66. Roberts LJ, Morrow JD. Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation [Review]. Cell Mol Life Sci 2002;59:808-20.
67. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology [Review]. Am J Physiol Lung Cell Mol Physiol 2001;280:L1067-82.
68. 2-Isoprostanes in Alzheimer and other neurodegenerative diseases [Review]. Antioxid Redox Signal 2005;7:269-75.
69. Schwedhelm E, Boger RH. Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease [Review]. Clin Chem Lab Med 2003;4:1552-61.
70. Moore KP, Holt SG, Patel RP, Svistunenko DA, Zackert W, Goodier D, et al. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J Biol Chem 1998;273:31731-7.
71. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans [Review]. Arterioscler Thromb Vasc Biol 2005;25:279-86.
72. 4 poisoning? Free Radic Biol Med 2005;38:698-710.
73. 2α excretion in man. J Pharmacol Exp Ther 1995;275:94-100.
74. Pratico D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine [Review]. Trends Endocrinol Metab 2001;12:243-7.
75. 2-Isoprostanes as indices of lipid peroxidation in inflammatory diseases [Review]. Chem Phys Lipids 2004;128:165-71.
76. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999;459:259-62.
77. Higdon JV, Liu J, Du SH, Morrow JD, Ames BN, Wander RC. Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes. Am J Clin Nutr 2000;72:714-22.
78. Montuschi P, Kharitonov SA, Ciabattoni G, Corradi M, van Rensen L, Geddes DM, et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 2000;55:205-9.
79. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-7.
80. Stojiljkovic MP, Lopes HF, Zhang D, Morrow JD, Goodfriend TL, Egan BM. Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster. J Hypertens 2002;20:1215-21.
81. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, et al. Urinary 8-iso-prostaglandin F2α as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109:843-8.
82. Tsikas D, Schwedhelm E, Fauler J, Gutzki FM, Mayatepek E, Frolich JC. Specific and rapid quantification of 8-iso-prostaglandin F2α in urine of healthy humans and patients with Zellweger syndrome by gas chromatography-tandem mass spectrometry. J Chromatogr B 1998;716:7-17.
83. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998;44:410-3.
84. 2α-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-12.
85. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972-6.
86. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002;52:175-9.
87. Bohnstedt KC, Karlberg B, Wahlund LO, Jonhagen ME, Basun H, Schmidt S. Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. J Chromatogr B 2003;796:11-9.
88. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000;50:377-9.
89. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16:1135-40.
90. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification [Review]. Clin Chim Acta 2003;333:19-39.
91. Capitan P, Malmezat T, Breuille D, Obled C. Gas chromatographic-mass spectrometric analysis of stable isotopes of cysteine and glutathione in biological samples. J Chromatogr B 1999;732:127-35.
92. Steghens JP, Flourie F, Arab K, Collombel C. Fast liquid chromatography-mass spectrometry glutathione measurement in whole blood: micromolar GSSG is a sample preparation artifact. J Chromatogr B 2003;798:343-9.
93. Rossi R, Milzani A, Dalle-Donne I, Giustarini D, Lusini L, Colombo R, et al. Blood glutathione disulfide: in vivo factor or in vitro artifact? Clin Chem 2002;48:742-53.
94. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. An improved HPLC measurement for GSH and GSSG in human blood. Free Radic Biol Med 2003;35:1365-72.
95. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. Interference of plasmatic glutathione and hemolysis on glutathione disulfide levels in human blood. Free Radic Res 2004;38:1101-6.
96. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease [Review]. Biochem Pharmacol 2002;64:1037-48.
97. Warner DS, Sheng H, Batinić-Haberle I. Oxidants, antioxidants and the ischemic brain [Review]. J Exp Biol 2004;207:3221-31.
98. Mills BJ, Weiss MM, Lang CA, Liu MC, Ziegler C. Blood glutathione and cysteine changes in cardiovascular disease. J Lab Clin Med 2000;135:396-402.
99. Navarro J, Obrador E, Carretero J, Petschen I, Avino J, Perez P, et al. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med 1999;26:410-8.
100. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N, Grune T. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med 1999;27:1080-6.
101. Comhair SA, Erzurum SC. Antioxidant responses to oxidant-mediated lung diseases [Review]. Am J Physiol Lung Cell Mol Physiol 2002;283:L246-55.
102. Lang CA, Mills BJ, Mastropaolo W, Liu MC. Blood glutathione decreases in chronic diseases. J Lab Clin Med 2000;135:402-5.
103. Lang CA, Mills BJ, Lang HL, Liu MC, Usui WM, Richie J Jr, et al. High blood glutathione levels accompany excellent physical and mental health in women ages 60 to 103 years. J Lab Clin Med 2002;140:413-7.
104. Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I. S-Glutathionylation: from redox regulation of protein functions to human diseases [Review]. J Cell Mol Med 2004;8:201-12.
105. Dalle-Donne I, Rossi R, Giustarini D, Colombo R, Milzani A. Is there a role for S-glutathionylation of proteins in human disease? IUBMB Life 2005;57:189-92.
106. Pastore A, Tozzi G, Gaeta LM, Bertini E, Serafini V, Di Cesare S, et al. Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia: a potential role in the pathogenesis of the disease. J Biol Chem 2003;43:42588-95.
107. van der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP, Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol 2000;279:L537-46.
108. Brennan ML, Wu W, Fu X, Shen Z, Song W, Frost H, et al. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem 2002;277:17415-27.
109. Gaut JP, Yeh GC, Tran HD, Byun J, Henderson JP, Richter GM, et al. Neutrophils employ the myeloperoxidase system to generate antimicrobial brominating and chlorinating oxidants during sepsis. Proc Natl Acad Sci U S A 2001;98:11961-6.
110. Gaut JP, Byun J, Tran HD, Heinecke JW. Artifact-free quantification of free 3-chlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionisation gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Biochem 2002;300:252-9.
111. Duncan MW. A review of approaches to the analysis of 3-nitrotyrosine [Review]. Amino Acids 2003;25:351-61.
112. Tsikas D, Caidahl K. Recent methodological advances in the mass spectrometric analysis of free and protein-associated 3-nitrotyrosine in human plasma. J Chromatogr B 2005;814:1-9.
113. Tsikas D, Mitschke A, Suchy MT, Gutzki FM, Stichtenoth DO. Determination of 3-nitrotyrosine in human urine at the basal state by gas chromatography- tandem mass spectrometry and evaluation of the excretion after oral intake. J Chromatogr B 2005;827:146-56.
114. Schwedhelm E, Tsikas D, Gutzki FM, Frölich JC. Gas chromatographic-tandem mass spectrometric quantification of free 3-nitrotyrosine in human plasma at the basal state. Anal Biochem 1999;276:195-203.
115. Frost MT, Halliwell B, Moore KP. Analysis of free and protein-bound nitrotyrosine in human plasma by a gas chromatography/mass spectrometry method that avoids nitration artifacts. Biochem J 2000;345:453-8.
116. Yi D, Ingelse BA, Duncan MW, Smythe GA. Quantification of 3-nitrotyrosine in biological tissues and fluids: generating valid results by eliminating artifactual formation. J Am Soc Mass Spectrom 2000;11:578-86.
117. Tsikas D, Schwedhelm E, Stutzer FK, Gutzki FM, Rode I, Mehls C, et al. Accurate quantification of basal plasma levels of 3-nitrotyrosine and 3-nitrotyrosinoalbumin by gas chromatography-tandem mass spectrometry. J Chromatogr B 2003;784:77-90.
118. Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman AL, Mocatta TJ, et al. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 2004;170:1317-23.
119. Pattison DI, Davies MJ. Kinetic analysis of the reactions of hypobromous acid with protein components: implications for cellular damage and use of 3-bromotyrosine as a marker of oxidative stress. Biochemistry 2004;43:4799-809.
120. Wu W, Samoszuk MK, Comhair SA, Thomassen MJ, Farver CF, Dweik RA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest 2000;105:1455-63.
121. MacPherson JC, Comhair SAA, Erzurum SC, Klein DF, Lipscomb MF, Kavuru MS, et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: Characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol 2001;166:5763-72.
122. Aldridge RE, Chan T, Van Dalen CJ, Senthilmohan R, Winn M, Venge P, et al. Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. Free Radic Biol Med 2002;33:847-56.
123. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004;101:13032-7.
124. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004;279:42977-83.
125. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41.
126. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99:2075-81.
127. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289:1675-80.
128. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
129. Gole MD, Souza JM, Choi I, Hertkorn C, Malcolm S, Foust RF III, et al. Plasma proteins modified by tyrosine nitration in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2000;278:L961-7.
130. Pignatelli B, Li CQ, Boffetta P, Chen Q, Ahrens W, Nyberg F, et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001;61:778-84.
131. Masri FA, Comhair SAA, Koeck T, Stuehr DJ, Xu W, Janocha A, et al. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 2005;172:597-605.
132. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? [Review]. J Clin Invest 2003;111:163-9.
133. Zhan X, Desiderio DM. The human pituitary nitroproteome: detection of nitrotyrosyl-proteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry. Biochem Biophys Res Commun 2004;325:1180-6.
134. Greenacre SA, Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction [Review]. Free Radic Res 2001;34:541-81.
135. Turko IV, Murad F. Protein nitration in cardiovascular diseases [Review]. Pharmacol Rev 2002;54:619-34.
136. Bhattacharjee S, Pennathur S, Byun J, Crowley J, Mueller D, Gischler J, et al. NADPH oxidase of neutrophils elevates o,o'dityrosine cross-links in proteins and urine during inflammation. Arch Biochem Biophys 2001;395:69-77.
137. Manary MJ, Leeuwenburgh C, Heinecke JW. Increased oxidative stress in kwashiorkor. J Pediatr 2000;137:421-4.
138. Giulivi C, Traaseth NJ, Davies KJ. Tyrosine oxidation products: analysis and biological relevance [Review]. Amino Acids 2003;25:227-32.
139. Malencik DA, Anderson SR. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 2003;25:233-47.
140. Orhan H, Coolen S, Meerman JH. Quantification of urinary o,o'-dityrosine, a biomarker for oxidative damage to proteins, by high performance liquid chromatography triple quadrupole tandem mass spectrometry: a comparison with ion-trap tandem mass spectrometry. J Chromatogr B 2005;827:104-8.
141. Orhan H, Vermeulen NP, Tump C, Zappey H, Meerman JH. Simultaneous determination of tyrosine, phenylalanine and deoxyguanosine oxidation products by liquid chromatography-tandem mass spectrometry as non-invasive biomarkers for oxidative damage. J Chromatogr B 2004;799:245-54.
142. Aldini G, Dalle-Donne I, Vistoli G, Maffei Facino R, Carini M. Covalent modification of actin by 4-hydroxy-frans-2-nonenal (HNE): LC-ESI-MS/MS evidence for Cys374 Michael adduction. J Mass Spectrom 2005;40:946-54.
143. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as a biomarkers of oxidative stress. Clin Chim Acta 2003;329:23-8.
144. Levine RL. Carbonyl modified proteins in cellular regulation, aging, and disease [Review]. Free Radic Biol Med 2002;32:790-6.
145. Butterfield DA, Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders [Review]. Amino Acids 2003;25:419-25.
146. Renke J, Popadiuk S, Korzon M, Bugajczyk B, Wozniak M. Protein carbonyl groups' content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis. Free Radic Biol Med 2000;29:101-4.
147. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-16.
148. Winterbourn CC, Bonham MJ, Buss H, Abu-Zidan FM, Windsor JA. Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis. Pancreatology 2003;3:375-82.
149. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 2002;32:1102-15.
150. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002;32:968-74.
151. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence [Review]. Mol Cell Biochem 2004;266:37-56.
152. Collins AR, Cadet J, Moller L, Poulsen HE, Vina J. Are we sure we know how to measure 8-oxo-7,8-dihydroguanine in DNA from human cells? Arch Biochem Biophys 2004;423:57-65.
153. Alary J, Gueraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways [Review]. Mol Aspects Med 2003;24:177-87.
154. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress: identification of proteasomes as target molecules. J Biol Chem 1999;274:23787-93.
155. Meagher EA, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, et al. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999;104:805-13.
156. 2α-III and an oxidation product of γ-linolenic acid. J Biol Chem 2000;275:2499-504.
157. Souza JM, Choi I, Chen Q, Weisse M, Daikhin E, Yudkoff M, et al. Proteolytic degradation of tyrosine nitrated proteins. Arch Biochem Biophys 2000;380:360-6.
158. Mani AR, Pannala AS, Orie NN, Ollosson R, Harry D, Rice-Evans CA, et al. Nitration of endogenous para-hydroxyphenylacetic acid and the metabolism of nitrotyrosine. Biochem J 2003;374:521-7.
159. Pannala AS, Mani AR, Spencer JPE, Skinner V, Bruckdorfer KR, Moore KP, et al. The effect of dietary nitrate on salivary, plasma, and urinary nitrate metabolism in humans. Free Radic Biol Med 2003;34:576-84.
160. Leeuwenburgh C, Hansen PA, Holloszy JO, Heinecke JW. Oxidized amino acids in the urine of aging rats: potential markers for assessing oxidative stress in vivo. Am J Physiol Regul Integr Comp Physiol 1999;276:128-35.
161. Leeuwenburgh C, Hansen PA, Holloszy JO, Heinecke JW. Hydroxyl radical generation during exercise increases mitochondrial protein oxidation and levels of urinary dityrosine. Free Radic Biol Med 1999;27:186-92.
162. Hazen SL, Crowley JR, Mueller DM, Heinecke JW. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase-catalyzed chlorination at sites of inflammation. Free Radic Biol Med 1997;23:909-16.
163. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: current state [Review]. Pharmacol Rev 2002;54:271-84.
164. Gilgun-Sherki Y, Melamed E, Offen D. Antioxidant treatment in Alzheimer's disease: current state [Review]. J Mol Neurosci 2003;21:1-11.
165. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-47.
166. x-induced nitration: assay for 3-nitrotyrdsine by HPLC with electrochemical detection. Proc Natl Acad Sci U S A 1997;94:3211-6.
167. Söderling AS, Ryberg H, Gabrielson A, Lärstad M, Toren K, Niari S, et al. A derivatization assay using gas chromatography/negative chemical ionization tandem mass spectrometry to quantify 3-nitrotyrosine in human plasma. J Mass Spectrom 2003;38:1187-96.
168. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, Crabb JW, et al. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci U S A 2001;98:12056-61.
169. Goen T, Muller-Lux A, Dewes P, Musiol A, Kraus T. Sensitive and accurate analyses of free 3-nitrotyrosine in exhaled breath condensate by LC-MS/MS. J Chromatogr B 2005;826:261-6.
170. 4 poisoning. Free Radic Biol Med 2005;38:711-8.
171. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath [Review]. Biomarkers 2002;7:1-32.
172. Rahman I, Kelly F. Biomarkers in breath condensate: a promising new non-invasive technique in free radical research [Review]. Free Radic Res 2003;37:1253-66.
173. Granger CB, Van Eyk JE, Mockrin SC, Anderson NL. National Heart, Lung, and Blood Institute Clinical Proteomics Working Group report. Circulation 2004;109:1697-703.
174. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-23
175. [Erratum published in: Lancet 2004;363:662].
176. Tousoulis D, Antoniades C, Stefanadis C. Nitric oxide in coronary artery disease: effects of antioxidants [Review]. Eur J Clin Pharmacol Oct 11, 2005:1-7 [Epub ahead of print].
177. Kocyigit A, Keles H, Selek S, Guzel S, Celik H, Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutat Res 2005;585:71-8.
178. Craghill J, Cronshaw AD, Harding JJ. The identification of a reaction site of glutathione mixed-disulphide formation on γS-crystallin in human lens. Biochem J 2004;379:595-600.
179. Ghezzi P, Romines B, Fratelli M, Eberini I, Gianazza E, Casagrande S, et al. Protein glutathionylation: coupling and uncoupling of glutathione to protein thiol groups in lymphocytes under oxidative stress and HIV infection. Mol Immunol 2002;38:773-80.
180. Hermo R, Mier C, Mazzotta M, Tsuji M, Kimure S, Gugliucci A. Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients. Clin Chem Lab Med 2005;43:601-6.
181. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005;48:1590-603.
182. Lorch SA, Banks BA, Christie J, Merrill JD, Althaus J, Schmidt K, et al. Plasma 3-nitrotyrosine and outcome in neonates with severe bronchopulmonary dysplasia after inhaled nitric oxide. Free Radic Biol Med 2003;34:1146-52.
183. Woods AA, Linton SM, Davies MJ. Detection of HOCI-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem J 2003;370:729-35.
184. Yuan Z, Shioji K, Nimata M, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis. Mol Cell Biochem 2004;259:223-7.
185. Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem 2003;248:93-5.
186. Rottoli P, Magi B, Cianti R, Bargagli E, Vagaggini C, Nikiforakis N, et al. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:2612-8.
187. Schaper M, Gergely S, Lykkesfeldt J, Zbaren J, Leib SL, Tauber MG, et al. Cerebral vasculature is the major target of oxidative protein alterations in bacterial meningitis. J Neuropathol Exp Neurol 2002;61:605-13.